Infiniwell
infiniwell.com ↗Company Overview
Infiniwell was founded in 2020 in Dallas, Texas by Odd Sandbekkhaug (CEO), and is linked to Bonasana Health Limited. The company’s primary differentiator is its use of SNAC (salcaprozate sodium) absorption-enhancing technology across its oral peptide products. BBB rating: B+ (not accredited), file opened July 2025.
Products & Pricing
| Product | Format | Price | Key Claim |
|---|---|---|---|
| BPC Rapid Pro | 60 capsules | ~$159.95 | BPC-157 + SNAC absorption technology |
| NMN products | Capsules | $80–$140 | Anti-aging/longevity |
| Metabolic line | Various | $60–$130 | Weight management |
| Topicals | Creams/serums | $50–$90 | Skin/joint support |
All oral peptide products contain salcaprozate sodium (SNAC) as an absorption enhancer.
The SNAC Question: This Is the Core Issue
SNAC has extensive published evidence for enhancing oral absorption — specifically of semaglutide. Novo Nordisk’s Rybelsus (oral semaglutide) uses SNAC technology licensed from Emisphere Technologies, and the supporting evidence is robust (Buckley ST et al., Sci Transl Med, 2018). The original composition-of-matter patent has expired, and SNAC has GRAS (Generally Recognized As Safe) status for use “in combination with nutrients added to food and dietary supplements.”
However, no published clinical study demonstrates that SNAC enhances oral bioavailability of BPC-157 specifically. SNAC’s enhancement mechanism involves creating locally elevated gastric pH and promoting transcellular absorption — effects that are molecule-specific. The fact that SNAC works for semaglutide (MW 4,114 Da, specific structure) does not guarantee it works for BPC-157 (MW 1,420 Da, completely different structure). This is not how pharmacology works.
Infiniwell reportedly partnered with OvationLab to produce a “landmark human study” on their BPC-157/SNAC combination. This study does not appear in PubMed or any peer-reviewed journal as of our review date. Company-commissioned, unpublished studies are marketing materials, not scientific evidence.
Transparency Assessment
Score: 45/100 — COAs are not publicly accessible on the website. The claim that “25,000+ healthcare professionals recommend InfiniWell” is unverified and appears to be marketing language without substantiation.
Testing & Quality
Score: 50/100 — Claims third-party testing but does not provide public, named-lab documentation. The presence of SNAC suggests some level of formulation sophistication, but without published validation, this is an input claim, not an outcome claim.
Pricing Assessment
Score: 30/100 — At ~$160 for a 60-capsule BPC-157 product, Infiniwell is among the most expensive options in the oral peptide market. The premium is justified by the SNAC technology — but since there’s no published evidence that SNAC actually enhances BPC-157 absorption, consumers are paying a premium for an unproven enhancement.
Regulatory Standing
No FDA warning letters identified. BBB B+ rating with no patterns of complaints. The NDI notification concern that applies to all BPC-157 supplement sellers also applies to Infiniwell.
Customer Experience
Trustpilot: 4.7/5 from 53 reviews — a positive score but from a modest review volume. Heavy affiliate marketing presence, which means many online “reviews” are financially incentivized.
Red Flags
- SNAC bioavailability claims extrapolated without evidence: The leap from “SNAC works for semaglutide” to “SNAC works for BPC-157” is not supported by published data
- Unpublished “landmark study”: Company-commissioned research that hasn’t been peer-reviewed should not be treated as evidence
- Premium pricing for unproven enhancement: Consumers pay more for technology that hasn’t been validated for this specific application
- Heavy affiliate marketing: Difficult to find truly independent reviews
- Unverifiable “25,000+ healthcare professionals” claim
The Bottom Line
Infiniwell’s business model rests on the SNAC bioavailability differentiator — and that differentiator is scientifically unsupported for BPC-157. The company may eventually publish peer-reviewed data validating their formulation, but until that happens, the premium pricing for SNAC-enhanced BPC-157 is based on an extrapolation, not evidence. If you’re going to take oral BPC-157 (with all the caveats noted in our BPC-157 profile), there’s no published reason to believe that Infiniwell’s formulation delivers more of it to your bloodstream than a cheaper product without SNAC.